VCU Joins Global Initiative to Accelerate Drug Development for Primary Sclerosing Cholangitis
核心洞察
VCU is partnering with PSC Partners (搜索) in the WIND-PSC (搜索) initiative to find treatments for primary sclerosing cholangitis (搜索) (PSC).
The five-year project aims to create a global database of 2,000 PSC (搜索) patients, gathering medical data and quality of life reports.
The initiative seeks to accelerate treatment development by serving as a comparison cohort for clinical trials and improving disease biomarkers.
A Virginia Commonwealth University (VCU) hepatologist is collaborating with PSC Partners (搜索) in a global effort to study primary sclerosing cholangitis (搜索) (PSC (搜索)) and accelerate the development of effective treatments. The initiative, known as the Worldwide Initiative for New Drug Development in PSC (WIND-PSC), aims to create a comprehensive database of PSC patient data to better understand the disease and identify potential therapeutic targets.
Sayed "Obi" Aseem, M.D., Ph.D., an assistant professor at VCU School of Medicine, has received a $445,526 grant to support VCU's participation in the five-year project. VCU is one of three U.S. sites selected for the project and the only one in the Mid-Atlantic region. Aseem aims to contribute data from over 100 patients to the study's goal of enrolling 2,000 patients.
Understanding Primary Sclerosing Cholangitis
PSC (搜索) is a chronic liver disease characterized by inflammation and scarring of the bile ducts, which carry digestive fluid from the liver to the small intestine. This scarring can lead to cirrhosis, liver failure, and the need for a liver transplant. According to PSC Partners (搜索), an estimated 30,000 people in the U.S. have PSC. "PSC is a rare liver disease, but with a significant disease burden, risk of malignancy and mortality," Aseem stated. "There are currently no treatments for PSC. So, in most patients, this is progressive to end-stage liver disease requiring a liver transplant or cancers of the liver."
The WIND-PSC Initiative
WIND-PSC (搜索) is establishing a large, global database of information on PSC patients, including medical data, symptoms, and quality of life reports. By collecting and analyzing this data, researchers hope to gain a deeper understanding of how PSC progresses and identify potential treatments. The initiative will assess participants annually with physical exams, lab tests, imaging, liver stiffness assessment, and markers for liver fibrosis. Clinical symptoms and events, medications, procedures, and patient-reported PSC symptoms will be gathered quarterly.
"The WIND-PSC (搜索) initiative will drastically accelerate the process of treatment development by serving as a comparison cohort for other clinical trials of specific interventions," Aseem explained. "It will also provide valuable information for better disease biomarkers and how to improve the symptoms and quality of life for those afflicted by this condition."
Patient Involvement
Patient involvement is a key component of the WIND-PSC (搜索) initiative. PSC Partners (搜索) emphasizes the importance of patient input in shaping the direction of research and ensuring that researchers understand what matters most to those living with the disease. Cynthia Levy, M.D., professor of medicine at the University of Miami and the project’s principal investigator, stated, "By working together, we believe this project can accelerate drug development and finally have an effective treatment for this disease."
PSC Partners (搜索) and PSC Partners Canada have committed $4 million in funding to the project and plan to expand to 16 new sites in Europe. This funding will support research sites, patient recruitment, and data management.